Use of heparin in patients with severe COVID-19: What is the evidence?
DOI:
https://doi.org/10.33448/rsd-v10i6.15820Keywords:
COVID-19; Heparin; SARS-CoV-2; Blood coagulation; Thrombosis; Anticoagulants.Abstract
The rapid spread of coronavirus disease (COVID-19) worldwide urges the need for studies on the illness and its management. The COVID-19 infection leads to hypercoagulation due to inflammatory cytokine release and D-dimer increase in critically ill patients, resulting in pulmonary thromboembolism (PE) and venous thromboembolism (VTE) evolving to sepsis and death. The study evaluated the currently existing evidence on heparin administration in patients with severe COVID-19. An integrative literature review was done by searching for scientific studies in the PubMed, Scopus, Embase, and Web of Science databases. The analyzed studies showed that heparin use in critically ill patients could efficiently prevent thrombotic events and reduce the exacerbated inflammatory process. However, further investigation on the effect on patients is still needed. The use of heparin in critically ill COVID-19 patients has been prescribed increasingly by doctors. But its use has not yet had its outcomes well established in the literature. Therefore, deeper investigations and new research development are needed to clarify potential beneficial effects.
References
Barnes, G. D., Burnett, A., Allen, A., Blumenstein, M., Clark, N. P., Cuker, A., Dager, W. E., Deitelzweig, S. B., Ellsworth, S., Garcia, D., Kaatz, S., & Minichiello, T. (2020). Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. Journal of thrombosis and thrombolysis, 50(1), 72–81. https://doi.org/10.1007/s11239-020-02138-z.
Bocchese, N. V., Dávila, N. G., Rodrigues, M. B. M., Araújo-Neto, I., Costa, M. O., et al. (2020). COVID-19 and Liver Injury: Hepatology Perspectives. J Clin Gastroenterol Treat. 74(6). 10.23937/2469-584X/1510074.
Boccia, M., Aronne, L., Celia, B., Mazzeo, G., Ceparano, M., D'Agnano, V., Parrella, R., Valente, T., Bianco, A., & Perrotta, F. (2020). COVID-19 and coagulative axis: review of emerging aspects in a novel disease. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 90(2), 10.4081/monaldi.2020.
Dantas, T. C. de A., Gomes, A. C. A., Lima, I. P. C., Lucas, B. B., Aguiar, M. R. de., Cavalcanti, T. C. de H., Pinheiro, F. I., Rêgo, A. C. M., & Araújo-Filho, I. (2021). Corticosteroid therapy in patients with severe COVID-19. Research, Society and Development, 10(1), e58910112114. https://doi.org/10.33448/rsd-v10i1.12114.
D’Souza, R., Malhamé, I., Teshler, L., Acharya, G., Hunt, B. J., & McLintock, C. (2020). A critical review of the pathophysiology of thrombotic complications and clinical practice recommendations for thromboprophylaxis in pregnant patients with COVID-19. Acta Obstet Gynecol Scand. 99. 1110– 1120. https://doi.org/10.1111/aogs.13962.
Goés, A. B. M., Cardoso, B. B., Tavares, F. A. F., do Monte, R. R. L., Melo, R. C., et al. (2020). COVID-19 and Nervous System: Under Estimated Clinical and Prognostic Aspects. Int J Neurol Neurother. 100(7). doi.org/10.23937/2378-3001/1410100.
Gómez-Mesa, J. E., Galindo-Coral, S., Montes, M. C., & Muñoz Martin, A. J. (2021). Thrombosis and Coagulopathy in COVID-19. Current problems in cardiology, 46(3), 100742. https://doi.org/10.1016/j.cpcardiol.2020.100742.
Guevara-Noriega, K. A., Lucar-Lopez, G. A., Nuñez, G., Rivera-Aguasvivas, L., & Chauhan, I. (2020). Coagulation Panel in Patients with SARS-CoV2 Infection (COVID-19). Annals of clinical and laboratory science, 50(3), 295–298.
Helms, J., Severac, F., Merdji, H., Schenck, M., Clere-Jehl, R., Baldacini, M., Ohana, M., Grunebaum, L., Castelain, V., Anglés-Cano, E., Sattler, L., & Meziani, F. (2021). Higher anticoagulation targets and risk of thrombotic events in severe COVID-19 patients: bi-center cohort study. Ann Intensive Care. 11(1). https://doi.org/10.1186/s13613-021-00809-5.
Iba, T., Warkentin, T. E., Thachil, J., Levi, M., & Levy, J. H. (2021). Proposal of the Definition for COVID-19-Associated Coagulopathy. Journal Of Clinical Medicine. 10(2), 191. https://doi.org/10.3390/jcm10020191.
Lindahl, U., & Li, J. P. (2020). Heparin - An old drug with multiple potential targets in Covid-19 therapy. Journal of thrombosis and haemostasis: JTH, 18(9), 2422–2424. https://doi.org/10.1111/jth.14898.
Maldonado, E., Tao, D., & Mackey, K. (2020). Antithrombotic Therapies in COVID-19 Disease: a Systematic Review. J GEN INTERN MED 35, 2698–2706. https://doi.org/10.1007/s11606-020-05906-y.
Marietta, M., Coluccio, V., & Luppi, M. (2020). COVID-19, coagulopathy and venous thromboembolism: more questions than answers. Internal and emergency medicine, 15(8), 1375–1387. https://doi.org/10.1007/s11739-020-02432-x.
Marinho, V. R. D., Abreu, C. A., Pereira, L. H. M., & Lemos, T. E. V. (2021). Aplicação de zinco em pacientes com COVID-19: o que há de evidência?. Science & Saúde: Atualizações sobre o COVID-19, 1(18), 170-179. https://doi.org/10.47402/ed.ep.c20212518201.
Menezes-Rodrigues, F. S., Tavares, J. G. P., Oliveira, M. P., Carvalho, R. G., Errante, P. R., Taha, M. O., Fagundes, D. J., & Caricati-Neto, A. (2020). Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients. Journal of thrombosis and haemostasis: JTH, 18(8), 2073–2075. https://doi.org/10.1111/jth.14902.
Miesbach, W., & Makris, M. (2020). COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation. Clinical and applied thrombosis/hemostasis: official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 26. https://doi.org/10.1177/1076029620938149.
Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia Da Pesquisa Científica (1st ed.). Santa Maria: Universidade Federal de Santa Maria.
Ranucci, M., Sitzia, C., Baryshnikova, E., Di Dedda, U., Cardani, R., Martelli, F., & Romanelli, M. C. (2020). Covid-19-Associated Coagulopathy: Biomarkers of Thrombin Generation and Fibrinolysis Leading the Outcome. Journal of Clinical Medicine, 9(11), 3487. https://doi.org/10.3390/jcm9113487.
Riveira-Caravaca, J. M., Nðñez-Gil, I. J., Vivas, D., Viana‐Llamas, M. C., Uribarri, A., Becerra-Muñoz, V. M., Trabattoni, D., Rozas, I. F., Feltes, G., & López-Pais, J. (2020). Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID‐19. European Journal Of Clinical Investigation, [S.L.], 51(1), 1-11. https://doi.org/10.1111/eci.13436.
Riveros, D., Maymó, D., Laviano, J., Fornillo, F. F., Fernández, J., Benzadon, R., Solimano, J., Cacchione, R., Riera, L., Duarte, P., Cazap, N., Gotta, D., García Altuve, J., Valentini, R., & Dupont, J. (2020). Coagulopatía y COVID-19. Recomendaciones para una realidad cambiante [Coagulopathy and COVID-19. Recommendations for a changing reality]. Medicina, 80(5), 505–511.
Seffer, M-T., Cottam, D., Fornic, L. G., & Kielsteina, J. T. (2020). Heparin 2.0: A New Approach to the Infection Crisis. Karger Journals, 50(1), 28-34. https://doi.org/10.1159/000508647.
Schmoch, T., Brenner, T., Becker-Pennrich, A., Hinske, L. C., Weigand, M. A., Briegel, J., Möhnle, P., & SepNet Study Group (2021). Therapie der sepsisinduzierten Koagulopathie: Ergebnisse einer deutschlandweiten Umfrage auf Intensivstationen [Treatment of sepsis-induced coagulopathy: Results of a Germany-wide survey in intensive care units]. Der Anaesthesist, 1–9. Advance online publication. https://doi.org/10.1007/s00101-021-00916-9.
Schulman, S. (2020). Coronavirus Disease 2019, Prothrombotic Factors, and Venous Thromboembolism. Semin Thromb Hemost. 46(7). 772-776. https://doi.org/10.1055/s-0040-1710337.
Stratton, C. W., Tang, Y., & Lu, H. (2020). Pathogenesis‐directed therapy of 2019 novel coronavirus disease. Journal Of Medical Virology. 93(3), 1320-1342. https://doi.org/10.1002/jmv.26610.
Tang, N., Bai, H., Chen, X., Gong, J., Li, D., & Sun, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of thrombosis and haemostasis: JTH, 18(5), 1094–1099. https://doi.org/10.1111/jth.14817.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Vitória Ribeiro Dantas Marinho; Camila Vilar Oliveira Villarim; Laura Cristina Costa e Silva; André Luiz Costa e Silva; Irami Araújo-Neto; Diego Maia Diogenes Rabelo Caldas; Amália Cinthia Meneses Rêgo; Irami Araújo-Filho
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
